Alimera Appoints Maggie A. Pax to Its Board of Directors
ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be...
Source: globenewswire.com
Rick Eiswirth News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Rick Eiswirth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Rick Eiswirth Today - Breaking & Trending Today
Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call Transcript
Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call Transcript October 26, 2023 Alimera Sciences, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.41. Operator: Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences Third Quarter 2022 [2023] (sic) Financial Results and Corporate Update Conference Call. [Operator […]
Source: yahoo.com
Alimera Sciences Inc (ALIM) Reports Q3 2023 Financial Results
Record net revenue and significant decrease in net loss highlight the quarter
Source: yahoo.com
Alimera Sciences, Inc. (NASDAQ:ALIM) Q2 2023 Earnings Call Transcript
Alimera Sciences, Inc. (NASDAQ:ALIM) Q2 2023 Earnings Call Transcript August 10, 2023 Alimera Sciences, Inc. misses on earnings expectations. Reported EPS is $-0.44 EPS, expectations were $0.06. Operator: Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences Second Quarter 2023 Financial Results Conference Call. [Operator Instructions]. I would […]
Source: yahoo.com
EyePoint Pharma Sells U.S. Rights to Eye Med to Become Pure Play Drug Developer
By selling U.S. rights to Yutiq, EyePoint Pharmaceuticals gets $75 million cash to support its drug pipeline. The company’s lead product candidate is in mid-stage development for wet age-related macular degeneration and non-proliferative diabetic retinopathy.
Source: medcitynews.com